Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma

Area of Science:

• Oncology
• Immunotherapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a rapidly advancing treatment modality.
• It is increasingly utilized for hematologic malignancies, particularly non-Hodgkin B-cell lymphoma.

Purpose of the Study:

• To provide a comprehensive review of CAR T-cell therapy in aggressive B-cell lymphoma.
• To cover clinical indications, toxicity profiles, efficacy mechanisms, and resistance patterns.

Main Methods:

• Literature review of clinical studies and research on CAR T-cell therapy.
• Analysis of data regarding treatment outcomes, adverse events, and biological mechanisms.

Main Results:

• CAR T-cell therapy demonstrates significant efficacy in treating aggressive B-cell lymphomas.
• Short- and long-term toxicities are well-documented and manageable.
• Mechanisms of both efficacy and tumor resistance are being elucidated.

Conclusions:

• CAR T-cell therapy represents a key therapeutic option for aggressive B-cell lymphoma.
• Ongoing research aims to optimize efficacy, mitigate toxicity, and overcome resistance.
• Future directions include refining CAR T-cell constructs and treatment strategies.